In the face of the recent rebound in coronavirus infection, the research team of the Faculty of Medicine (CU Med) at the Chinese University of Hong Kong (CUHK) conducted a study on older patients in nursing homes. The result proves that two oral antivirals, Molnupiravir and Nirmatrelvir/ Ritonavir, known as Paxlovid, can lower the risk of hospitalization and inpatient disease progression by 54 percent and 65 to 83 percent, respectively.
CU Medicine collected data from 14,617 older people in Hong Kong diagnosed with COVID-19 between February and March 2022, who are under the care of community elderly assessment teams.
The study subjects aged between 83 to 85 on average. Among them, 35 percent were prescribed Molnupiravir, 3.3 percent took Nirmatrelvir/ Ritonavir, and 61.2 percent did not use oral antivirals….